Samsung Biologics Secures Record 1.7 Trillion KRW Contract

Samsung Biologics has made headlines again. On the 22nd, the company announced that it had signed a massive Contract Manufacturing Organization (CMO) deal worth 1.7028 trillion KRW ($1.24 billion) with a pharmaceutical company based in Asia. This deal is the largest in the company’s history, nearly half of its total orders from last year (3.5009 trillion KRW). Due to confidentiality agreements, the client and product details were not disclosed, and the contract runs until December 31, 2037.

This deal follows another major contract signed in July, worth 1.46 trillion KRW, with a U.S.-based pharmaceutical company. In just three months, Samsung Biologics has broken its previous record for the largest order.

For the first time since its founding, the company’s annual cumulative orders have surpassed 4 trillion KRW. Since the first deal in March this year, Samsung Biologics has secured a total of nine deals with global pharmaceutical companies, bringing its cumulative order total for the year to 4.36 trillion KRW. This marks an achievement 20% above last year’s total in just 10 months.

Samsung Biologics now counts 17 of the top 20 global pharmaceutical companies among its clients. Thanks to its exceptional manufacturing capacity, quality control, and track record, the company’s total cumulative orders since its founding have surpassed $15.4 billion (21.3 trillion KRW).

To meet the increasing global demand for biopharmaceuticals, Samsung Biologics is also expanding its production capacity. The fifth plant, designed to incorporate the best practices from plants 1 to 4, is under construction and set to become operational in April 2025. Once completed, Samsung Biologics will have a total production capacity of 784,000 liters.

In terms of quality, Samsung Biologics has demonstrated competitiveness by achieving a 99% batch success rate in its manufacturing and management processes. As of September, the company had secured 39 approvals from the U.S. FDA and 34 from the European Medicines Agency (EMA), totaling 326 global regulatory approvals in just 13 years. Samsung Biologics also claims to have one of the highest inspection pass rates in the industry.

A representative from Samsung Biologics said, “This year, we’ve strengthened our business networking and order activities by participating in major pharmaceutical and biotech conferences across the U.S., Europe, and Asia. We also plan to open a sales office in Tokyo, Japan, to further strengthen our partnerships with clients as part of our global expansion efforts.”